首页> 美国卫生研究院文献>Frontiers in Cellular and Infection Microbiology >Visceral Leishmaniasis IgG1 Rapid Monitoring of Cure vs. Relapse and Potential for Diagnosis of Post Kala-Azar Dermal Leishmaniasis
【2h】

Visceral Leishmaniasis IgG1 Rapid Monitoring of Cure vs. Relapse and Potential for Diagnosis of Post Kala-Azar Dermal Leishmaniasis

机译:内脏利什曼病IgG1快速监测治愈与复发的关系以及诊断卡拉·阿扎尔皮肤性利什曼病的潜力

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

>Background: There is a recognized need for an improved diagnostic test to assess post-chemotherapeutic treatment outcome in visceral leishmaniasis (VL) and to diagnose post kala-azar dermal leishmaniasis (PKDL). We previously demonstrated by ELISA and a prototype novel rapid diagnostic test (RDT), that high anti-Leishmania IgG1 is associated with post-treatment relapse versus cure in VL.>Methodology: Here, we further evaluate this novel, low-cost RDT, named VL Sero K-SeT, and ELISA for monitoring IgG1 levels in VL patients after treatment. IgG1 levels against L. donovani lysate were determined. We applied these assays to Indian sera from cured VL at 6 months post treatment as well as to relapse and PKDL patients. Sudanese sera from pre- and post-treatment and relapse were also tested.>Results: Of 104 paired Indian sera taken before and after treatment for VL, when deemed clinically cured, 81 (77.9%) were positive by VL Sero K-SeT before treatment; by 6 months, 68 of these 81 (84.0%) had a negative or reduced RDT test line intensity. ELISAs differed in positivity rate between pre- and post-treatment (p = 0.0162). Twenty eight of 33 (84.8%) Indian samples taken at diagnosis of relapse were RDT positive. A comparison of Indian VL Sero K-SeT data from patients deemed cured and relapsed confirmed that there was a significant difference (p < 0.0001) in positivity rate for the two groups using this RDT. Ten of 17 (58.8%) Sudanese sera went from positive to negative or decreased VL Sero K-SeT at the end of 11–30 days of treatment. Forty nine of 63 (77.8%) PKDL samples from India were positive by VL Sero K-SeT.>Conclusion: We have further shown the relevance of IgG1 in determining clinical status in VL patients. A positive VL Sero K-SeT may also be helpful in supporting diagnosis of PKDL. With further refinement, such as the use of specific antigens, the VL Sero K-SeT and/or IgG1 ELISA may be adjuncts to current VL control programmes.
机译:>背景:公认需要改进的诊断测试,以评估内脏利什曼病(VL)的化疗后治疗结果以及诊断黑热病后皮肤利什曼病(PKDL)。我们先前通过ELISA和原型新型快速诊断测试(RDT)证明,高抗利什曼原虫IgG1与VL中治疗后的复发与治愈相关。>方法:在这里,我们将进一步评估这种新型,低成本RDT(称为VL Sero K-SeT)和ELISA监测治疗后VL患者中IgG1的水平。测定抗多诺威尼酵母溶解物的IgG1水平。我们将这些检测方法应用于治疗后6个月治愈的VL以及复发和PKDL患者的印度血清。 >结果::在治疗VL之前和之后服用的104对印度血清中,经临床治愈后,苏丹血清为81份(77.9%)为阳性治疗前VL Sero K-SeT;到6个月时,这81个中的68个(84.0%)的RDT测试线强度为负或降低。在治疗前后,ELISA的阳性率有所不同(p = 0.0162)。在诊断出复发的33份印度样本中,有28份(84.8%)为RDT阳性。比较来自被认为已治愈和复发的患者的印度VL Sero K-SeT数据,证实使用该RDT两组的阳性率存在显着差异(p <0.0001)。在治疗的11至30天结束时,苏丹血清中的十种(58.8%)从阳性变为阴性或VL血清K-SeT降低。 VL Sero K-SeT在来自印度的63个PKDL样本中有49个呈阳性。>结论:我们进一步显示了IgG1在确定VL患者临床状况中的相关性。 VL Sero K-SeT阳性也可能有助于支持PKDL的诊断。通过进一步改进,例如使用特定抗原,VL Sero K-SeT和/或IgG1 ELISA可以作为当前VL控制程序的辅助工具。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号